07.06.2023 • Topics

Opportunities and Limits of Sustainability

The Pharmaceutical industry must prioritize sustainability. Jürgen Roos, Chief Scientific Officer (CSO) of Siegfried, explains opportunities and limits of sustainability.

CHEManager: How do you improve the environmental footprint of your production processes at Siegfried?

Jürgen Roos: We prioritize our sustainability efforts based on environmental impact. For example, we experiment with alternatives to harmful chemicals. Or we fundamentally redesign a manufacturing process by using more creative and innovative chemistry. This includes bio-transformations, in which enzymes catalyze highly selective reactions.

How much sustainability is possible? Where are the limits?

J. Roos: To give you an example: With our expertise in process optimization, we have reduced the number of process steps in the production of one of our APIs from 17 to 10, saving large amounts of solvent, energy and raw materials, and reducing process waste. The limit is often time: this research effort took over six years and cost nearly 2 million Dollar.

What are the biggest challenges? And do investments in sustainability outweigh the financial benefits that you ultimately gain from them?

J. Roos: Sustainability and operational efficiency go hand in hand and investments always pay off over the long run. However, the optimization of production processes is resource and manpower intensive, one reason being that a new process requires a new regulatory approval. More regulatory flexibility would incentivize companies to revisit their production processes to make them more sustainable.

Author: Thorsten Schüller, CHEManager

Jürgen Roos, Chief Scientific Officer (CSO), Siegfried © Siegfried
Jürgen Roos, Chief Scientific Officer (CSO), Siegfried © Siegfried

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read